Synthesis, Radiolabeling, and Preclinical Evaluation of 68Ga/177Lu-Labeled Leuprolide Peptide Analog for the Detection of Breast Cancer

被引:4
|
作者
Okarvi, Subhani M. [1 ]
Al-Jammaz, Ibrahim [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Cyclotron & Radiopharmaceut Dept, MBC 03,POB 3354, Riyadh 11211, Saudi Arabia
关键词
leuprolide; breast cancer; radiolabeling; peptide synthesis; biodistribution; GONADOTROPIN-RELEASING-HORMONE; EMISSION-TOMOGRAPHY RADIOPHARMACEUTICALS; GNRH ANALOGS; RECEPTORS; BOMBESIN; THERAPY; IMPACT; TOOLS;
D O I
10.1089/cbr.2021.0370
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The expansion of novel and potent tumor receptor binding peptides is a promising approach for the precise targeting of various cancer. Leuprolide is a 9-residue peptide analog of gonadotropin-releasing hormone and is extensively used in the treatment of sex hormone-dependent tumors, including prostate, breast, and ovarian cancer. This preclinical study was undertaken to prepare a new radiolabeled leuprolide peptide for the detection of breast carcinoma.Methods: A 1,4,7,10-tetraazacyclododecane-N,N ',N '',N '''-tetraacetic acid (DOTA)-coupled 9-amino acid leuprolide peptide was synthesized after typical 9-fluorenylmethyl-oxycarbonyl-based solid-phase peptide synthesis and radiolabeled with both Ga-68 and Lu-177 radionuclides for theranostic use. The systemic pharmacokinetics was done in healthy balb/c mice. The in vitro tumor cell binding affinity was determined on MCF7, T47D, and MDA-MB-231 breast cancer cell lines. In vivo tumor targeting and micro positron-emission tomography imaging was performed on nude mice with MCF7 breast tumor xenografts.Results: The leuprolide peptide was conveniently synthesized by solid-phase synthesis strategy and its identity and purity were validated by mass spectrometry and high-performance liquid chromatography. The peptide radiolabeled efficiently (>94%) with both diagnostic (Ga-68) and therapeutic (Lu-177) radionuclides and displayed nanomolar binding potency to all three tested MCF7, T47D, and MDA-MB-231 cell lines. Fast and favorable pharmacokinetics was observed for Ga-68/Lu-177-leuprolide in healthy Balb/c mice. In nude mice, Ga-68-leuprolide peptide exhibited rapid clearance from the blood circulation with low to moderate (up to 5% ID/g) uptake/retention by the major body organs. The accumulation in the estrogen receptor-positive MCF7 tumor was 2.24% +/- 0.62% ID/g at 45 min p.i, with good tumor to blood and muscle uptake ratios. The radiolabeled peptide was excreted primarily through the renal pathway.Conclusion: The encouraging results of this initial study demonstrate that additional testing of this leuprolide peptide seems to be indicated because of its convincing potential to be a new agent for the management of breast carcinoma.
引用
收藏
页码:372 / 383
页数:12
相关论文
共 50 条
  • [21] Synthesis and Evaluation of 68Ga- and 177Lu-Labeled [Pro14]bombesin(8-14) Derivatives for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer
    Wang, Lei
    Kuo, Hsiou-Ting
    Chapple, Devon E.
    Chen, Chao-Cheng
    Kurkowska, Sara
    Colpo, Nadine
    Uribe, Carlos
    Benard, Francois
    Lin, Kuo-Shyan
    MOLECULAR PHARMACEUTICS, 2024, 21 (12) : 6385 - 6397
  • [22] Preclinical imaging and radiotherapy of prostate cancer using the theranostic twins(68Ga/177Lu)-radiolabeled peptides
    Lim, J. C.
    Cho, E. H.
    Lee, S. Y.
    Dho, S. H.
    Kim, S. Y.
    Jung, S. H.
    RADIOTHERAPY AND ONCOLOGY, 2016, 118 : S67 - S68
  • [23] Synthesis and Evaluation of 68Ga- and 177Lu-Labeled [diF-Pro14]Bombesin(6-14) Analogs for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer
    Wang, Lei
    Chen, Chao-Cheng
    Chapple, Devon
    Wong, Antonio A. W. L.
    Kurkowska, Sara
    Lau, Wing Sum
    Uribe, Carlos F.
    Benard, Francois
    Lin, Kuo-Shyan
    PHARMACEUTICALS, 2025, 18 (02)
  • [24] Preclinical evaluation of novel theranostic heterodimeric ligands [68Ga]Ga/[177Lu]Lu-DOTA-FAPI-BPsfor tumor bone metastasis
    Deng, Y.
    Jin, W.
    Zhang, Z.
    Wang, X.
    Zhao, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S450 - S450
  • [25] Preclinical Evaluation of a 68Ga/177Lu-based CXCR4 Radioligand: A Theranostic Tool Against Advanced Prostate Cancer
    Astiazaran-Rascon, I.
    Kuo, H.
    Merkens, H.
    Colpo, N.
    Ng, P.
    Ong, C.
    Wang, Y.
    Lin, K.
    Benard, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S64 - S64
  • [26] A preclinical evaluation of Ga-68 labeled NODAGA and DOTA peptide conjugates to image breast cancer.
    Kumar, Pardeep
    Tripathi, Sushil
    Mehta, Neil
    Wickstrom, Eric
    Thakur, Mathew
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [27] Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer
    Qi Yang
    Zhao Chen
    Yongkang Qiu
    Wenpeng Huang
    Tianyao Wang
    Lele Song
    Xinyao Sun
    Cuicui Li
    Xiaojie Xu
    Lei Kang
    European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51 : 1246 - 1260
  • [28] Preclinical pharmacokinetics evaluation of four novel 177Lu-labeled gastrin-releasing peptide receptor-targeted ligands: comparison with 177Lu-AMBA and 177Lu-RM2
    Wang, Lei
    Kuo, Hsiou-Ting
    Chapple, Devon
    Merkens, Helen
    Colpo, Nadine
    Ng, Pauline
    Lau, Wing Sum
    Wilson, Ryan
    Benard, Francois
    Lin, Kuo-Shyan
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [29] 68Ga/177Lu labeled bivalent imaging agents targeting hypoxia and PSMA in tumors
    Luo, Y.
    Jin, W.
    Wang, R.
    Hong, H.
    Zhao, R.
    Yan, L.
    Huang, Y.
    Qiao, J.
    Zhu, L.
    Kung, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S462 - S462
  • [30] Development of 68Ga/177Lu-LNC1011 for theranostics of prostate cancer
    Yang, Hongzhang
    Wen, Xuejun
    Guo, Huifeng
    Zhang, Jingjing
    Zhou, Zijian
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65